Nattokinase is a unmatched and strong systemic enzyme obtained by fermenting non-GMO soya beans. Nattokinase is used for cardiovascular diseases including heart disease, stroke, angina, deep vein thrombosis, hardening of the arteries, high blood pressure, varicose veins, poor circulation, and peripheral artery disease stroke, venous stasis, thrombosis, emboli, retinal pathology, claudication and varicose veins. Natto is produced by a fermentation process by adding Bacillus natto, a benefical bacteria, to boiled soybeans. Nattokinase was discovered over 20 years ago by Japanese researcher Dr. Hiroyuki Sumi after testing 173 different types of food in search of an alternative to warfarin to help reduce the effect of blood clots on blood circulation. This property was subsequently confirmed by animal and in vivo studies.
Natural Blood Thinners Nattokinase
This enzyme is known for anti-clotting (fibrinolytic) capacities. Successfully dissolves fibrin and increases the system’s natural ability to keep blood vessels clean. Functions of nattokinase include directly degrading a fibrin, activating pro-urokinase and increasing the amount of tissue plasminogen activator (t-PA) that produces a thrombolytic enzyme, plasmin. Furthermore, new researches has revealed that nattokinase has a function of degrading plasminogen activator inhibitor, PAI-1 and reducing the euglobulin lysis time, and therefore it has a effect of improving the thrombolytic activity. Researches with nattokinase indicates that it may help prevent or lessen the likelihood of deep vein thrombosis, cardiac infarction, pulmonary emboli and stroke.
Nattokinase is considered to be the most powerful fibrinolytic enzyme ever discovered. In addition to having direct fibrinolytic actions, can also increase the body’s own production of plasmin, as well as several other agents that assist in dissolving blood clots. In light of the findings supporting nattokinase, Dr. Martin Milner from the Center for Natural Medicine has stated that nattokinase is not only highly effective in breaking down a thrombus, but seems to be even more strong than the standard “clot-busting” medications. Nattokinase enhances the body’s natural ability to fight blood clots and has an advantage over blood thinners because it has a prolonged effect without side effects. A major difference between nattokinase and blood thinning drugs is that the drugs interfere with the production of fibrin and due to this interference, blood thinning drugs have significant side-effects. Nattokinase acts upon the fibrin itself, which is a metabolic end-product.
Nattokinase was shown to reduce the aggregation of red blood cells in vitro in a study done at the ‘University of Los Angeles in California‘. A study reported in the 2010 edition of the Acta Haematologica found that nattokinase decreased blood-clot formation in animals. Researchers tested Nattokinase’s effect to dissolve a blood clot in the carotid arteries of rats. Animals treated with nattokinase enzyme regained 62% of blood flow, whereas those treated with plasmin regained only 15 % of blood flow.
A study performed with natto on 12 healthy participants sought to indicate fibrinolytic activity. The participants were given natto before breakfast, than their fibrinolytic activity was tested over time. The findings demonstrate natto generates an increased ability to dissolve blood clots. On average, the participants’ ELT dropped by 48% within two hours of treatment, and participants retained an enhanced ability to dissolve blood clots for 2 to 8 hours. In a study following 238 high-risk individuals for stroke, the researchers showed a significant relationship between increased CCA-IMT and the occurrence of myocardial infarction and stroke. For each increment of 0.1 mmin common carotid artery intima-media thickness (CCA-IMT), the probability of experiencing recurrent stroke increased by 18.0%. The development of edema, and both superficial and DVT (deep vein thrombosis) is not uncommon in long-haul flights, especially in high-risk people. In a study high-risk individuals on long-haul flights were supplemented with a combination product containing nattokinase and pycnogenol. Two capsules were taken 2 hours before the flight and again 6 hours later. As result, the nattokinase combination product decreased thrombotic events and controlled edema in the individuals. Also, the difference between the nattokinase group and the control group was statistically significant.